Sarolaner for Canine Generalized Demodicosis: Efficacy, Class Pharmacology, and Safety

Bottom line

• Sarolaner is an oral isoxazoline acaricide that, given monthly, eliminates Demodex canis mites in dogs with generalized demodicosis; in a pivotal masked field study a sarolaner-moxidectin-pyrantel combination reached 100% mean live-mite reduction by Day 90 and was non-inferior to an afoxolaner-milbemycin oxime comparator.[1]
• Across two randomized studies (130 dogs), mites fell 99.2% by Day 29 in the laboratory arm with no live mites detected thereafter, and clinical signs improved in all treated dogs.[1]
• A critically appraised topic concludes that afoxolaner, fluralaner and sarolaner, alongside macrocyclic lactones, can all achieve parasitological and clinical cure of canine mange, but head-to-head comparative data remain limited.[2]
• Isoxazolines act by blocking arthropod GABA- and glutamate-gated chloride channels with much higher affinity for invertebrate than mammalian receptors, which underlies their wide safety margin; rare but serious neurological adverse events have been reported, particularly in dogs with impaired drug efflux (for example ABCB1/MDR1 variants).[3]
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Isoxazoline acaricide/insecticide (often co-formulated with the macrocyclic lactone moxidectin and the anthelmintic pyrantel).[3]
• Mechanism: Non-competitive antagonism of GABA-gated and L-glutamate-gated chloride channels in arthropods, producing sustained neuronal hyperexcitation and parasite death; affinity is markedly higher for arthropod than mammalian receptors.[3]
• Route/interval: Oral; administered monthly in the demodicosis studies (defer the specific dose to current labeling and your formulary).[1]
• Indication discussed here: Generalized demodicosis (Demodex canis) in dogs; isoxazolines are also used for sarcoptic mange.[1][2]
• Pharmacokinetic class traits: High lipophilicity, extensive plasma protein binding, large volume of distribution, low clearance and long elimination half-life.[3]
• Reported class safety signal: Rare serious neurological adverse events, particularly in predisposed animals or with impaired efflux transport (ABCB1/MDR1 mutation, P-glycoprotein inhibition).[3]

A specific patient on demodicosis?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=sarolaner-canine-generalized-demodicosis

What the evidence shows

Efficacy in generalized demodicosis

The most directly relevant data come from a 2025 report of two randomized, masked studies in 130 dogs with generalized demodicosis, comparing an oral sarolaner-moxidectin-pyrantel combination (SMP) with oral afoxolaner plus milbemycin oxime (AM).[1] In the laboratory study, dogs received three monthly treatments with biweekly mite counts. SMP reduced mite counts by 88.8% on Day 14 and by 99.2% on Day 29, after which no live mites were detected; the difference between the two treatment groups was not statistically significant (p = 0.96).[1]

In the field study, mite counts and clinical evaluations were performed monthly and treatment continued until two consecutive skin scrapings were negative. SMP produced reductions in arithmetic mean live mite counts of 92.4%, 98.1%, 100% and 100% on Days 30, 60, 90 and 120, and was non-inferior to the comparator on Days 30 and 60.[1] Both products were tolerated well, and clinical signs of demodicosis improved in all dogs.[1] The authors concluded that monthly SMP eliminated Demodex mites after two monthly treatments in the laboratory study and at most after three monthly treatments in the field study.[1]

Where sarolaner sits among systemic options

A critically appraised topic on the most effective systemic treatment for canine mange reviewed the comparative evidence across drug classes.[2] It found that afoxolaner, fluralaner and sarolaner, as well as several macrocyclic lactones such as selamectin, moxidectin and milbemycin oxime, can all lead to parasitological and clinical cure.[2] The authors emphasized that the clinical and parasitological efficacy of these substances is broadly similar, which strengthens the case for direct comparative studies to identify the single most efficacious product — a gap that still limits firm ranking of one isoxazoline over another.[2] That review focused on sarcoptic mange, but it situates sarolaner within the same isoxazoline class now used routinely for Demodex.

Mechanism and class pharmacology

Sarolaner belongs to the isoxazoline class alongside fluralaner, afoxolaner and lotilaner.[3] A 2026 pharmacology and toxicology review describes these compounds as highly lipophilic, fluorinated molecules whose biologically active S-enantiomers improve potency while limiting off-target effects.[3] They act through non-competitive antagonism of GABA- and L-glutamate-gated chloride channels in arthropods, producing sustained neuronal hyperexcitation and parasite death, with markedly higher affinity for arthropod than mammalian receptors.[3] Pharmacokinetically, the class shares extensive plasma protein binding, large volumes of distribution, low clearance and long elimination half-lives, which underpin prolonged efficacy.[3]

How this fits clinical practice

The published data support sarolaner-containing oral isoxazolines as an effective option for generalized canine demodicosis, with monthly dosing continued to parasitological cure (two consecutive negative scrapings).[1] Because controlled studies generally show wide safety margins but post-marketing surveillance has identified rare serious neurological adverse events — particularly in animals with impaired efflux transport such as ABCB1/MDR1 variants or concurrent P-glycoprotein inhibition — a medication and breed history is reasonable before treatment, and any neurological signs warrant prompt reassessment.[3] Comparative head-to-head data between individual isoxazolines remain limited, so product selection still rests on labeling, availability and clinical judgment rather than a proven efficacy ranking.[2] Do not infer specific doses from this summary; confirm the regimen, monitoring schedule and contraindications against current product labeling and a veterinary formulary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=sarolaner-canine-generalized-demodicosis

References

1. Becskei C, Liebenberg J, Fernandes T, Borowski S, D'Hanis L, Mahabir SP. 2025. Efficacy of a chewable tablet containing sarolaner, moxidectin and pyrantel for the treatment of generalised demodicosis in dogs. Vet Dermatol 36(1):34-42. https://europepmc.org/article/MED/39469982
2. Dumitrache MO, Cadiergues MC. 2023. The most effective systemic treatment in dogs with sarcoptic mange: a critically appraised topic. BMC Vet Res 19(1):189. https://europepmc.org/article/MED/37798627 [via]
3. Markowska-Bunka P, Rasinski B, Ziolkowski H. 2026. Pharmacology and toxicology of veterinary isoxazolines: a review. Int J Parasitol Drugs Drug Resist 31:100645. https://europepmc.org/article/MED/42013589 [via]

Changelog

• 2026-06-21: First published.

Related reads

• Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
• Cyclosporine (Atopica) for Canine Atopic Dermatitis: Efficacy, Safety, and Clinical Place
• Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence